Cover Image
Market Research Report

Hepatitis B - Pipeline Review, H2 2017

Published by Global Markets Direct Product code 232823
Published Content info 380 Pages
Immediate Delivery Available
Price
Back to Top
Hepatitis B - Pipeline Review, H2 2017
Published: November 14, 2017 Content info: 380 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2017, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 7, 27, 26, 4, 64, 38 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9897IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatitis B - Overview
  • Hepatitis B - Therapeutics Development
  • Hepatitis B - Therapeutics Assessment
  • Hepatitis B - Companies Involved in Therapeutics Development
  • Hepatitis B - Drug Profiles
  • Hepatitis B - Dormant Projects
  • Hepatitis B - Discontinued Products
  • Hepatitis B - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatitis B, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hepatitis B - Pipeline by Abivax SA, H2 2017
  • Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2017
  • Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2017
  • Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2017
  • Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Altimmune Inc, H2 2017
  • Hepatitis B - Pipeline by Altravax Inc, H2 2017
  • Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2017
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2017
  • Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2017
  • Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2017
  • Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2017
  • Hepatitis B - Pipeline by Biological E Ltd, H2 2017
  • Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2017
  • Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Bukwang Pharm Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Hepatitis B - Pipeline by CaroGen Corp, H2 2017
  • Hepatitis B - Pipeline by Celltrion Inc, H2 2017
  • Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Chromis Therapeutics Inc, H2 2017
  • Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2017
  • Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by CyTuVax BV, H2 2017
  • Hepatitis B - Pipeline by DelSiTech Oy, H2 2017
  • Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2017
  • Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2017
  • Hepatitis B - Pipeline by Enyo Pharma SA, H2 2017
  • Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2017
  • Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Hepatitis B - Pipeline by GeneCure LLC, H2 2017
  • Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2017
  • Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2017
  • Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Hepatitis B - Pipeline by Green Cross Corp, H2 2017
  • Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Huons Global Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Immunotope Inc, H2 2017
  • Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2017
  • Hepatitis B - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2017
  • Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2017
  • Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Johnson & Johnson, H2 2017
  • Hepatitis B - Pipeline by Kineta Inc, H2 2017
  • Hepatitis B - Pipeline by LG Chem Ltd, H2 2017
  • Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by Medivir AB, H2 2017
  • Hepatitis B - Pipeline by Mucosis BV (Inactive), H2 2017
  • Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2017
  • Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2017
  • Hepatitis B - Pipeline by Pfenex Inc, H2 2017
  • Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2017
  • Hepatitis B - Pipeline by Profarma, H2 2017
  • Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2017
  • Hepatitis B - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Replicor Inc, H2 2017
  • Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2017
  • Hepatitis B - Pipeline by Samjin Pharm Co Ltd, H2 2017
  • Hepatitis B - Pipeline by Sanofi, H2 2017
  • Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2017
  • Hepatitis B - Pipeline by Scynexis Inc, H2 2017
  • Hepatitis B - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
  • Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2017
  • Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017
  • Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2017
  • Hepatitis B - Pipeline by Theravectys SA, H2 2017
  • Hepatitis B - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017
  • Hepatitis B - Pipeline by Transgene SA, H2 2017
  • Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2017
  • Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2017
  • Hepatitis B - Pipeline by Vical Inc, H2 2017
  • Hepatitis B - Pipeline by ViroStatics srl, H2 2017
  • Hepatitis B - Pipeline by VLP Biotech Inc, H2 2017
  • Hepatitis B - Dormant Projects, H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Hepatitis B - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Hepatitis B, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top